Carregant...
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
CDK4/6 inhibitors have emerged as a powerful class of agents with clinical activity in a number of malignancies. Targeting the cell cycle represents a core attack on a defining feature of cancer. However, the mechanisms through which selective CDK4/6 targeted agents act has few parallels in the curr...
Guardat en:
| Publicat a: | Trends Cancer |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5347397/ https://ncbi.nlm.nih.gov/pubmed/28303264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trecan.2016.11.006 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|